Breaking News Instant updates and real-time market news.

KNL

Knoll

$20.00

-0.02 (-0.10%)

, HMST

HomeStreet

$28.60

-0.25 (-0.87%)

17:17
10/23/17
10/23
17:17
10/23/17
17:17

On The Fly: After Hours Movers

UP AFTER EARNINGS: Knoll (KNL), up 12.5%... HomeStreet (HMST), up 4.9%... Crane (CR), up 1.1%. ALSO HIGHER: Impax (IPXL), up 5.2% after it announced FDA approval and launch of its generic Renvela... Intercept (ICPT), up 2.2% after it announced "positive" results from its Phase 2 AESOP trial... Stanley Black & Decker (SWK), up 1% after it named Nike (NKE) CIO Jim Scholefield to its board of directors. DOWN AFTER EARNINGS: HNI Corporation (HNI), down 15.5%... Whirlpool (WHR), down 6.2%... Zions Bancorp (ZION), down 0.9%... John Bean Technologies (JBT), down 0.3%. ALSO LOWER: Immune Design (IMDZ), down 18.3% after it filed to sell 16M shares of common stock... Corbus Pharmaceuticals (CRBP), down 4.1% after it filed to sell common stock... uniQure (QURE), down 3.4% after it filed to sell 5M shares of common stock.

KNL

Knoll

$20.00

-0.02 (-0.10%)

HMST

HomeStreet

$28.60

-0.25 (-0.87%)

CR

Crane

$83.61

-0.5 (-0.59%)

IPXL

Impax

$20.35

-0.9 (-4.24%)

ICPT

Intercept

$65.60

-1.25 (-1.87%)

SWK

Stanley Black & Decker

$158.19

-1.93 (-1.21%)

NKE

Nike

$53.66

0.6 (1.13%)

HNI

HNI Corporation

$42.29

-0.57 (-1.33%)

WHR

Whirlpool

$182.50

0.04 (0.02%)

ZION

Zions Bancorp

$46.39

-0.37 (-0.79%)

JBT

John Bean Technologies

$104.05

0.1 (0.10%)

IMDZ

Immune Design

CRBP

Corbus Pharmaceuticals

$7.40

-0.375 (-4.82%)

QURE

uniQure

$18.52

-0.75 (-3.89%)

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 06

    Nov

  • 08

    Nov

  • 09

    Nov

  • 09

    Nov

  • 13

    Nov

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

KNL Knoll
$20.00

-0.02 (-0.10%)

08/28/17
08/28/17
UPGRADE

Outperform
Knoll upgraded to Outperform at Raymond James
As previously reported, Raymond James upgraded Knoll to Outperform from Market Perform and established a $20 price target. Analyst Budd Bugatch views valuation as attractive and said Knoll is well positioned to drive revenue growth as the macro environment for office furniture normalizes given an increased sales force, new product offerings, and competitive pricing.
08/16/17
SIDC
08/16/17
INITIATION
SIDC
Buy
Knoll initiated with a Buy at Sidoti
Sidoti initiated Knoll with a Buy and a $28 price target.
08/28/17
RAJA
08/28/17
UPGRADE
RAJA
Outperform
Knoll upgraded to Outperform from Market Perform at Raymond James
11/04/16
GHSC
11/04/16
INITIATION
Target $27
GHSC
Buy
Knoll initiated with a Buy at Seaport Global
Seaport Global analyst Matt McCall initiated Knoll with a Buy and a $27 price target. The analyst would take advantage of recent weakness saying concerns about softer commercial markets are overstated.
HMST HomeStreet
$28.60

-0.25 (-0.87%)

12/20/16
12/20/16
DOWNGRADE
Target $33

Market Perform
HomeStreet downgraded to Market Perform from Outperform at FBR Capital
FBR Capital analyst Paul Miller downgraded HomeStreet to Market Perform saying the current valuation fairly reflects the strength of the U.S. mortgage market and the company's diversification efforts. The analyst raised his price target for the shares to $33 from $32.
04/28/17
FIGP
04/28/17
DOWNGRADE
FIGP
Market Perform
HomeStreet downgraded to Market Perform from Outperform at Fig Partners
11/14/16
SDLR
11/14/16
DOWNGRADE
SDLR
Hold
HomeStreet downgraded to Hold from Buy at Sandler O'Neill
Sandler O'Neill analyst Tim O'Brien downgraded HomeStreet to Hold with a $60 price target citing recent share strength.
CR Crane
$83.61

-0.5 (-0.59%)

07/26/17
OPCO
07/26/17
NO CHANGE
Target $88
OPCO
Outperform
Crane selloff creates opportunity, says Oppenheimer
Oppenheimer analyst Jim Giannakouros says Crane's selloff after the company reported an in-line quarter creates opportunity. The analyst sees Crane as well positioned to be a growth and margins/returns outlier within his coverage given solid market positions and an execution track record. Giannakouros reiterated an Outperform rating on the stock but lowered his price target on the shares to $88 from $90.
07/26/17
BOFA
07/26/17
NO CHANGE
Target $90
BOFA
Buy
Crane pullback overdone, says BofA/Merrill
BofA/Merrill analyst Kristine Liwag said Crane weakness attributed to a more conservative tone in guidance regarding its ability to hit the high-end of 2017 guidance of $4.35-$4.55 is overdone. Liwag said there is no significant change in end-market outlook and continues to expect strong operating leverage in Fluid Handling to drive earnings in 2018 and beyond. The analyst rates Crane a Buy with a $90 price target.
08/14/17
WOLF
08/14/17
UPGRADE
WOLF
Outperform
Crane upgraded to Outperform from Peer Perform at Wolfe Research
07/11/17
WOLF
07/11/17
INITIATION
WOLF
Peer Perform
Crane initiated with a Peer Perform at Wolfe Research
IPXL Impax
$20.35

-0.9 (-4.24%)

10/17/17
BMOC
10/17/17
NO CHANGE
BMOC
Market Perform
Impax combination with Amneal makes strategic sense, says BMO Capital
BMO Capital analyst Gary Nachman thinks the combination of Impax with Amneal makes strategic sense as the two face a more challenging generic environment. He also believes the valuation of Impax had already been "somewhat stretched" amid news reports and investor speculation that such a deal would be coming. Nachman keeps a Market Perform rating on Impax shares, which are down nearly 9% in midday trading.
10/17/17
BMOC
10/17/17
NO CHANGE
Target $18
BMOC
Market Perform
Impax merger makes strategic sense, says BMO Capital
BMO Capital analyst Gary Nachman believes Impax Laboratories' merger with privately held Amneal makes strategic sense given the challenging generic environment. With Impax's valuation "already stretched," management will execute on the pipeline to drive a greater premium, Nachman tells investors in an intraday research note. He keeps a Market Perform rating on Impax.
09/28/17
GSCO
09/28/17
INITIATION
Target $20
GSCO
Neutral
Impax initiated with a Neutral at Goldman Sachs
Goldman analyst Dana Flanders Impax with a Neutral and $20 price target. The analyst sees downside risk to 2018 generic fundamentals given lack of sustainable R&D and said shares trade at a significant premium to peers.
10/18/17
ADAM
10/18/17
NO CHANGE
Target $19
ADAM
Hold
Impax deal positive but value creation may take time, says Canaccord
Canaccord analyst Dewey Steadman said he is positive on Impax's deal to combine with Amneal, but he expects the value creation to gradually come over time as the new company delivers on growth expectations well above its generic peers given its newly-created critical mass. Steadman maintained his Hold rating and $19 price target on Impax shares.
ICPT Intercept
$65.60

-1.25 (-1.87%)

10/02/17
RBCM
10/02/17
NO CHANGE
RBCM
Enanta data positive, says RBC Capital
RBC Capital analyst Brian Abrahams says that preclinical data on Enanta's (ENTA) EDP-305 presented at the AASLD conference "shows comparable-to-better effects on fibrosis to other anti-fibrotic agents." The analyst says that although the test was done on rats, other anti-fibrotic agents' impact on fibrosis in rats has been similar to their impact on fibrosis in humans. The analyst adds that the data indicates that EDP-305 may have a more beneficial effect on cholesterol genes than Intercept's (ICPT) Ocaliva drug. The analyst predicts that Phase I data on Enanta's drug, expected to be presented at the end of the conference, to be positive and potentially cause the shares to rise. He keeps an Outperform rating on Enata.
10/04/17
JMPS
10/04/17
DOWNGRADE
JMPS
Market Perform
Intercept downgraded to Market Perform from Outperform at JMP Securities
10/04/17
10/04/17
DOWNGRADE

Market Perform
Intercept downgraded on reduced NASH expectations at JMP Securities
As previously reported, JMP Securities analyst Liisa Bayko downgraded Intercept to Market Perform from Outperform after she adjusted her assumptions for market penetration of Ocaliva in NASH given the rapidly evolving competitive landscape and cases of serious liver injury and deaths reported in Ocaliva-treated PBC patients. The analyst, who has removed cirrhotic patients from her NASH model to be conservative, now believes Intercept is fairly valued at current levels.
10/06/17
GHSC
10/06/17
INITIATION
Target $136
GHSC
Buy
Intercept initiated with a Buy at Seaport Global
Seaport Global analyst Vernon Bernardino initiated Intercept with a Buy and $136 price target. The analyst expects Q4 prescription trends will support growing confidence that the FDA's statement has not had a longterm effect on Ocaliva Rx behavior in its approved use in patients with primary biliary cholangitis.
SWK Stanley Black & Decker
$158.19

-1.93 (-1.21%)

10/18/17
ZELM
10/18/17
UPGRADE
ZELM
Buy
Stanley Black & Decker upgraded to Buy from Hold at Zelman
10/20/17
10/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. eBay (EBAY) initiated with a Neutral at Guggenheim. 2. General Mills (GIS) initiated with a Hold at Jefferies. 3. Vistra Energy (VST) initiated with an Outperform at Evercore ISI. 4. American Homes 4 Rent (AMH) initiated with a Buy at Citi. 5. Stanley Black & Decker (SWK) initiated with a Buy at Northcoast. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/20/17
NRCS
10/20/17
INITIATION
Target $193
NRCS
Buy
Stanley Black & Decker initiated with a Buy at Northcoast
Northcoast analyst Thomas Hayes initiated Stanley Black & Decker with a Buy and price target $193.
10/18/17
WELS
10/18/17
NO CHANGE
Target $175
WELS
Outperform
Stanley Black & Decker price target raised to $175 from $165 at Wells Fargo
Wells Fargo analyst Rich Kwas raised his price target for Stanley Black & Decker to $175 from $165 ahead of quarterly results. The analyst reiterates an Outperform rating on the shares.
NKE Nike
$53.66

0.6 (1.13%)

10/16/17
COWN
10/16/17
NO CHANGE
COWN
Amazon will price activewear aggressively, may enter babies, says Cowen
Cowen analyst John Kernan says conversations over the weekend with supply chain contacts indicate Amazon.com (AMZN) will be aggressive with pricing in the activewear market and is sourcing from similar fabric suppliers as Nike (NKE), lululemon (LULU) and Under Armour (UAA). Contacts also suggest Amazon may develop intimates, baby and basics, which is a risk to Hanesbrands (HBI) and Carter's (CRI), Kernan tells investors in a research note dated yesterday titled "Amazonian Apparel Is A Clear Negative For Mass Market Brands." He believes Amazon's announcement Friday that it will source, design and market an athletic apparel line is a "clear negative for the mass market area of the category." It will create additional supply and deflation in a category that already has "inventory piled high in the U.S. wholesale channel," Kernan argues.
10/19/17
10/19/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Nike (NKE) downgraded to Neutral from Buy at Goldman Sachs with analyst Lindsay Drucker Mann saying shares will trade in a range as Nike works through excess inventory in the U.S. and next week's investor day is unlikely to be a positive catalyst. 2. Sprint (S) downgraded to Neutral from Outperform at Macquarie with analyst Amy Young saying a T-Mobile (TMUS) merger with Sprint could be imminent, but preliminary deal terms are not as attractive as she initially expected, especially speculation SoftBank (SFTBY) may be willing to accept market price in an all-equity deal. 3. Hain Celestial (HAIN) downgraded to Market Perform from Outperform at BMO Capital with analyst Amit Sharma saying valuation reflects a challenging operating environment. 4. Allergan (AGN) downgraded to Neutral from Buy at Mizuho. 5. MAA (MAA) downgraded to Market Perform from Outperform at JMP Securities with analyst Aaron Hecht saying shares are fairly valued as they approach his previous price target of $110. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/20/17
JEFF
10/20/17
NO CHANGE
Target $48
JEFF
Hold
Jefferies sees 'increasing probability' of Nike hitting $35 per share
Jefferies analyst Randal Konik admits the market knows Nike needs to lower its growth expectations. The analyst, however, views the company's "ubiquitous distribution" as the "real canary in the coal mine." Further, the market share gains by adidas (ADDYY) are "unrelenting," Konik told investors earlier in a research note. He sees earnings and multiple risk ahead for Nike as the market views the company as more "cyclical" and less of a "staple." The analyst has a base case of $48 per share and downside case of $35 per share. The latter's probability is increasing as share losses mount, Konik writes in his note titled "3 ISSUES HERE: Distro Model Extended, Share Loss Rising, Valuation Expensive." The analyst keeps a Hold rating on Nike with a $48 price target. The stock in early trading is up 1% to $53.34.
10/19/17
GSCO
10/19/17
DOWNGRADE
Target $54
GSCO
Neutral
Nike downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Lindsay Drucker Mann downgraded Nike to Neutral with an unchanged price target of $54. The shoemaker closed yesterday up 30c to $52.30. The shares will trade in a range as Nike works through excess inventory in the U.S. and next week's investor day is unlikely to be a positive catalyst, Mann tells investors in a research note. The analyst believes the valuation remains supported in the low-20s price-to-earnings ratio.
HNI HNI Corporation
$42.29

-0.57 (-1.33%)

02/28/17
SIDC
02/28/17
UPGRADE
SIDC
Buy
HNI Corporation upgraded to Buy from Neutral at Sidoti
Sidoti upgraded HNI Corporation to Buy citing the recent pullback in the shares.
01/06/17
SIDC
01/06/17
INITIATION
SIDC
Neutral
HNI Corporation initiated with a Neutral at Sidoti
08/23/17
08/23/17
UPGRADE
Target $42

Outperform
HNI Corporation upgraded to Outperform on valuation at Raymond James
As previously reported, Raymond James upgraded HNI Corporation to Outperform from Market Perfom and established a $42 price target. Analyst Budd Bugatch changed his view citing year-to-date weakness and well above market yield.
08/23/17
RAJA
08/23/17
UPGRADE
RAJA
Outperform
HNI Corporation upgraded to Outperform from Market Perform at Raymond James
WHR Whirlpool
$182.50

0.04 (0.02%)

07/28/17
RBCM
07/28/17
NO CHANGE
RBCM
Whirlpool should be bought on weakness, says RBC Capital
RBC Capital analyst Robert Wetenhall says that Whirplool's guidance cut was caused by "near-term headwinds." He believes that the company's competitive position and free cash flow remain strong, while the current valuation has created an attractive entry point. The analyst recommends buying the shares on weakness.
07/20/17
JPMS
07/20/17
NO CHANGE
JPMS
Whirlpool pullback on Amazon-Sears team-up overdone, says JPMorgan
JPMorgan analyst Michael Rehaut said he believes the decline in Whirlpool (WHR) following news of Sears' (SHLD) deal to sell appliances via Amazon (AMZN) has been overdone. He notes Whirlpool has proven it can adapt to the changing retail environment and that if Amazon becomes a reasonably large distribution channel for appliances he'd expect the company to participate.
06/22/17
FBCO
06/22/17
INITIATION
Target $208
FBCO
Neutral
Whirlpool initiated with a Neutral at Credit Suisse
Credit Suisse analyst Susan Maklari initiated Whirlpool with a Neutral and a $208 price target saying margin pressure from rising raw material costs, increasing competition, and the changing consumer environment keep risk/reward less attractive.
10/06/17
MKMP
10/06/17
NO CHANGE
Target $177
MKMP
Neutral
Some impact of ITC decision on Whirlpool largely priced in, says MKM Partners
MKM Partners analyst Megan McGrath says that while the latest ITC ruling in favor of Whirlpool and against South Korean manufacturers of washing machines is a "general positive" for at least a year, the 10% run-up in stock since late August has priced in some of the good news. There are still uncertainties around the remedy from the ITC decision as well as response from the competition, writes McGrath in her research note, adding that she remains cautious on the company's execution in Europe and the headwinds from steel price inflation. The analyst maintains her Neutral rating and $177 price target on Whirlpool.
ZION Zions Bancorp
$46.39

-0.37 (-0.79%)

08/28/17
RHCO
08/28/17
NO CHANGE
RHCO
Texas bank weakness creates buying opportunity, says SunTrust
SunTrust analyst Jennifer Demba predicts that the flooding in Texas will negatively impact the stocks of banks based in the state. She thinks that the "probable" weakness of the following bank stocks will create buying opportunities: Zions Bancorp (ZION), Cullen/Frost (CFR), Prosperity Bancshares (PB), and Texas Capital (TCBI).
09/08/17
BARD
09/08/17
UPGRADE
BARD
Neutral
Zions Bancorp upgraded to Neutral from Underperform at Baird
10/02/17
BARD
10/02/17
DOWNGRADE
BARD
Underperform
Zions Bancorp downgraded to Underperform from Neutral at Baird
10/02/17
BARD
10/02/17
DOWNGRADE
Target $43
BARD
Underperform
Zions Bancorp downgraded to Underperform at Baird
As reported previously, Baird analyst David George downgraded Zions Bancorp to Underperform from Neutral based on valuation. The analyst sees the need for accelerating loan growth and improvement in operating leverage to further narrow the spread in core returns versus peers. George has a $43 price target on Zions Bancorp shares.
JBT John Bean Technologies
$104.05

0.1 (0.10%)

06/02/17
JPMS
06/02/17
INITIATION
Target $88
JPMS
Neutral
John Bean Technologies initiated with a Neutral at JPMorgan
JPMorgan analyst C. Stephen Tusa started John Bean Technologies with a Neutral rating and $88 price target. The analyst sees some risk to fiscal year organic profit guidance and recommends looking for a more attractive entry point.
05/18/17
05/18/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. John Bean Technologies (JBT) initiated with a Neutral at BofA/Merrill. 2. PTC (PTC) initiated with a Buy at Benchmark. 3. Colfax (CFX) initiated with an Outperform at Credit Suisse. 4. Citizens Financial (CFG) initiated with an Underperform at Macquarie. 5. Teladoc (TDOC) initiated with an Overweight at KeyBanc. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/02/17
06/02/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Synergy Pharmaceuticals (SGYP) initiated with an Overweight at Cantor. 2. Fastenal (FAST) was initiated with an Overweight at Stephens and a Neutral at JPMorgan. 3. Ericsson (ERIC) was reinstated with a Buy at BofA/Merrill while Nokia (NOK) was reinstated with a Neutral. 4. John Bean Technologies (JBT) initiated with a Neutral at JPMorgan. 5. Biocept (BIOC) initiated with a Buy at Chardan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/18/17
BOFA
05/18/17
INITIATION
Target $89
BOFA
Neutral
John Bean Technologies initiated with a Neutral at BofA/Merrill
BofA/Merrill initiated John Bean Technologies with a Neutral and an $89 price target saying it may face headwinds from increasing low-cost competition and the pace of M&A.
IMDZ Immune Design

10/17/17
RBCM
10/17/17
NO CHANGE
Target $23
RBCM
Outperform
Immune Design weakness a buying opportunity, says RBC Capital
RBC Capital said Outperform rated Immune Design's positive FDA feedback on Phase III Trial for CMB305 is a de-risking event. The firm's analyst said the timeline could be pushed back slightly, but improves ultimate POS, while maintaining optionality. RBC recommends buying shares on weakness and raised the price target on shares to $23 from $20 .
09/14/17
RBCM
09/14/17
INITIATION
Target $20
RBCM
Outperform
Immune Design initiated with an Outperform at RBC Capital
RBC Capital analyst Brian Abrahams started Immune Design with an Outperform rating and $20 price target.
10/17/17
WELS
10/17/17
DOWNGRADE
WELS
Market Perform
Immune Design downgraded to Market Perform from Outperform at Wells Fargo
CRBP Corbus Pharmaceuticals
$7.40

-0.375 (-4.82%)

09/20/17
CANT
09/20/17
NO CHANGE
Target $24
CANT
Overweight
Corbus data 'encouraging supportive' for prior study, says Cantor
Cantor Fitzgerald analyst Elemer Piros reiterates an Overweight rating and $24 price target on Corbus Pharmaceuticals, following release of abstracts from the American College of Rheumatology meeting scheduled for November 3-8. Previously placebo-treated patients in one abstract began to demonstrate a meaningful response when treated with anabasum, while previously treated anabasum patients continued to improve response, Piros tells investors in a research note. He views these data as "encouraging supportive" for the prior Phase 2 study.
05/09/17
CANT
05/09/17
NO CHANGE
Target $24
CANT
Corbus poised to enter late stage development in 2017, says Cantor
Cantor Fitzgerald analyst Elemer Piros reiterates an Overweight rating and $24 price target on Corbus Pharmaceuticals' following its Q1 report, stating that the company is poised to enter late stage development in 2017 and noting that anabasum has fast track status and is eligible for priority review and submission through a rolling NDA.
09/29/17
NBLE
09/29/17
INITIATION
NBLE
Buy
Corbus Pharmaceuticals coverage assumed with a Buy at Noble Financial
Noble Financial analyst Caroline Palomeque assumed coverage of Corbus with a $16 price target and a Buy rating. The analyst believes that the launch of several trials of the company's Anabasum drug and the announcement of data on the drug from several other trials will be positive catalysts for the stock.
09/29/17
09/29/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Regeneron (REGN) assumed with an Overweight at Piper Jaffray. 2. MasterCard (MA) and Visa (V) were initiated with an Overweight at Cantor Fitzgerald. 3. Liberty Global (LBTYA, LBTYK) and Liberty Global LiLAC (LILA) were initiated with a Buy at Buckingham. 4. Corbus Pharmaceuticals (CRBP) coverage assumed with a Buy at Noble Financial. 5. Medpace (MEDP) initiated with a Market Perform at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
QURE uniQure
$18.52

-0.75 (-3.89%)

12/05/16
LEER
12/05/16
NO CHANGE
Target $9
LEER
Outperform
uniQure price target lowered to $9 from $23 at Leerink
Leerink analyst Joseph Schwartz assumed coverage of uniQure with an Outperform rating and lowered the price target on the shares to $9 from $23. The analyst believes the company's leadership and expertise in gene therapy should be a positive over the long-term, but resolutions to a number of uncertainties, questions, and optimizations remain essential in the near-term to enthuse investors.
11/22/16
JEFF
11/22/16
DOWNGRADE
Target $8
JEFF
Hold
uniQure downgraded to Hold from Buy at Jefferies
Jefferies analyst Eun Yang downgraded uniQure to Hold citing execution risks and a lack of near-term catalysts. uniQure's strategic review and prioritization announced last week "comes up short" in providing confidence in the company's strategy and execution, Yang tells investors in a research note. She cut her price target for the shares to $8 from $28.
06/29/17
OPCO
06/29/17
NO CHANGE
Target $17
OPCO
Outperform
Oppenheimer doctor survey supports bullish view on uniQure
Oppenheimer analyst Hartaj Singh says his firm's recent survey of 25 hematologists and oncologists supports his "continued bullish view" on uniQure. The survey suggests physician dissatisfaction with current treatments and a positive response to uniQure's blinded AMT-060 product profile, Singh tells investors in a research note. The analyst sees potential for 60% market penetration in three years after approval. He keeps an Outperform rating on uniQure with a $17 price target.
11/28/16
JANY
11/28/16
NO CHANGE
Target $12
JANY
Buy
uniQure price target lowered to $12 from $18 at Janney Capital
Janney Capital analyst Debjit Chattopadhyay acknowledged he has "been wrong on" uniQure so far and cut his fair value estimate on the stock to $12 from $18, adding that the upcoming Hemophilia B update at the ASH meeting "may not be [a] big enough catalyst for the stock." However, he keeps a Buy rating on uniQure shares, as he believes the bottom "could be probably close at hand" and the company's cash balance is sufficient to fund operations into 2019 while its major programs are still intact.

TODAY'S FREE FLY STORIES

VCEL

Vericel

$3.85

0.05 (1.32%)

, SNY

Sanofi

$44.93

0.61 (1.38%)

14:30
11/21/17
11/21
14:30
11/21/17
14:30
Hot Stocks
Vericel higher after CareFirst deems ACI medically necessary »

CareFirst announced…

VCEL

Vericel

$3.85

0.05 (1.32%)

SNY

Sanofi

$44.93

0.61 (1.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

DKS

Dick's Sporting

$28.40

-0.7 (-2.41%)

14:30
11/21/17
11/21
14:30
11/21/17
14:30
Options
Dicks Sporting Goods draws put writing »

Dicks Sporting Goods…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

GE

General Electric

$17.88

-0.105 (-0.58%)

14:20
11/21/17
11/21
14:20
11/21/17
14:20
Options
Repeat action in GE »

Repeat action in GE. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
11/21/17
11/21
14:17
11/21/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
11/21/17
11/21
14:16
11/21/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSK

GlaxoSmithKline

$34.91

-0.21 (-0.60%)

, PFE

Pfizer

$35.61

0.2648 (0.75%)

14:05
11/21/17
11/21
14:05
11/21/17
14:05
Hot Stocks
FDA approves ViiV Healthcare's two drug HIV treatment Juluca »

The FDA today said it…

GSK

GlaxoSmithKline

$34.91

-0.21 (-0.60%)

PFE

Pfizer

$35.61

0.2648 (0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 07

    Dec

  • 14

    Dec

OCLR

Oclaro

$6.49

-0.09 (-1.37%)

14:05
11/21/17
11/21
14:05
11/21/17
14:05
Options
Oclaro call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

  • 12

    Dec

NUE

Nucor

$56.02

0.46 (0.83%)

14:04
11/21/17
11/21
14:04
11/21/17
14:04
Hot Stocks
Nucor announces plans to build rebar micro mill »

Nucor announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTK

Cytokinetics

$11.10

-0.7 (-5.93%)

14:01
11/21/17
11/21
14:01
11/21/17
14:01
Recommendations
Cytokinetics analyst commentary  »

Cytokinetics price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CYTK

Cytokinetics

$11.10

-0.7 (-5.93%)

13:59
11/21/17
11/21
13:59
11/21/17
13:59
Recommendations
Cytokinetics analyst commentary  »

Cytokinetics price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

SSNLF

Samsung

, WHR

Whirlpool

$166.91

1.71 (1.04%)

13:58
11/21/17
11/21
13:58
11/21/17
13:58
Periodicals
ITC calls for tariff-rate quota on imported Samsung, LG washers, Reuters says »

The U.S. International…

SSNLF

Samsung

WHR

Whirlpool

$166.91

1.71 (1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RF

Regions Financial

$15.70

-0.16 (-1.01%)

13:55
11/21/17
11/21
13:55
11/21/17
13:55
Options
Regions Financial put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLMT

Calumet Specialty Products

$8.30

0.1 (1.22%)

13:53
11/21/17
11/21
13:53
11/21/17
13:53
Hot Stocks
Calumet Specialty Products announces divestiture of Anchor Drilling Fluids »

Calumet Specialty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITUS

ITUS

$3.16

0.25 (8.59%)

13:53
11/21/17
11/21
13:53
11/21/17
13:53
Conference/Events
ITUS to hold a pharmaceutical update conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENBL

Enable Midstream

$15.03

-0.0315 (-0.21%)

13:49
11/21/17
11/21
13:49
11/21/17
13:49
Downgrade
Enable Midstream rating change  »

Enable Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STLY

Stanley Furniture

$0.93

0.0349 (3.92%)

13:47
11/21/17
11/21
13:47
11/21/17
13:47
Hot Stocks
Stanley Furniture to sell substantially all its assets »

As previously reported,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
11/21/17
11/21
13:40
11/21/17
13:40
General news
NY Fed's overnight reverse repo totaled $42.9 B (19 counterparties) »

NY Fed's overnight…

EYE

National Vision

$30.19

0.21 (0.70%)

13:33
11/21/17
11/21
13:33
11/21/17
13:33
Initiation
National Vision initiated  »

National Vision initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CYTK

Cytokinetics

$11.10

-0.7 (-5.93%)

13:32
11/21/17
11/21
13:32
11/21/17
13:32
Downgrade
Cytokinetics rating change  »

Cytokinetics downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

LOW

Lowe's

$81.59

0.13 (0.16%)

13:27
11/21/17
11/21
13:27
11/21/17
13:27
Recommendations
Lowe's analyst commentary  »

Lowe's price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

WHR

Whirlpool

$165.67

0.47 (0.28%)

13:25
11/21/17
11/21
13:25
11/21/17
13:25
Periodicals
ITC suggests tariffs on washing machine imports above 1.2M units, Bloomberg says »

Two of four ITC officials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWI

Armstrong World

$53.70

-0.15 (-0.28%)

13:25
11/21/17
11/21
13:25
11/21/17
13:25
Conference/Events
Armstrong World to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

BMO

Bank of Montreal

$77.39

0.06 (0.08%)

13:21
11/21/17
11/21
13:21
11/21/17
13:21
Hot Stocks
BMO Financial Group enters partnership with CDL-Montreal »

BMO Financial Group and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$88.93

0.66 (0.75%)

13:20
11/21/17
11/21
13:20
11/21/17
13:20
Options
Buyer lays out 500K for three month upside in Procter and Gamble »

Buyer lays out 500K for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:20
11/21/17
11/21
13:20
11/21/17
13:20
General news
Fed Governor Powell's hearings for the position as Fed Chair »

Fed Governor…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.